Inextricable association of connective tissue disease with B‑cell lymphoma (Review)
- Authors:
- Jing-Shu Ruan
- Shan Xu
- Ning-Ning Shan
-
Affiliations: Department of Hematology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Department of Obstetrics, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China - Published online on: April 1, 2025 https://doi.org/10.3892/mco.2025.2843
- Article Number: 48
-
Copyright: © Ruan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Wang SS, Vajdic CM, Linet MS, Slager SL, Voutsinas J, Nieters A, de Sanjose S, Cozen W, Alarcón GS, Martinez-Maza O, et al: Associations of non-Hodgkin lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. Am J Epidemiol. 181:406–421. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Cereser L, Passarotti E, De Pellegrin A, Patruno V, Poi ED, Marchesini F, Zuiani C and Girometti R: Chest high-resolution computed tomography in patients with connective tissue disease: Pulmonary conditions beyond ‘the usual suspects’. Curr Probl Diagn Radiol. 51:759–767. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Khanmohammadi S, Shabani M, Tabary M, Rayzan E and Rezaei N: Lymphoma in the setting of autoimmune diseases: A review of association and mechanisms. Crit Rev Oncol Hematol. 150(102945)2020.PubMed/NCBI View Article : Google Scholar | |
|
Stern M, Buser AS, Lohri A, Tichelli A and Nissen-Druey C: Autoimmunity and malignancy in hematology-more than an association. Crit Rev Oncol Hematol. 63:100–110. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Ehrenfeld M, Abu-Shakra M, Buskila D and Shoenfeld Y: The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 27:750–756. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Váróczy L, Gergely L, Zeher M, Szegedi G and Illés A: Malignant lymphoma-associated autoimmune diseases-a descriptive epidemiological study. Rheumatol Int. 22:233–237. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundström C, Akerman M, Melbye M, Glimelius B and Adami HO: Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 98:51–60. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Mariette X: Lymphomas in patients with Sjögren's syndrome: Review of the literature and physiopathologic hypothesis. Leuk Lymphoma. 33:93–99. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, Macintyre E, Cerf-Bensussan N and Brousse N: Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French coeliac disease study group. Lancet. 356:203–208. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G and Hughes G: Systemic lupus erythematosus. Nat Rev Dis Primers. 2(16039)2016.PubMed/NCBI View Article : Google Scholar | |
|
Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S, Ginzler E, et al: Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 64:1507–1509. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Azrielant S, Tiosano S, Watad A, Mahroum N, Whitby A, Comaneshter D, Cohen AD and Amital H: Correlation between systemic lupus erythematosus and malignancies: A cross-sectional population-based study. Immunol Res. 65:464–469. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pettersson T, Pukkala E, Teppo L and Friman C: Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 51:437–439. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Cibere J, Sibley J and Haga M: Systemic lupus erythematosus and the risk of malignancy. Lupus. 10:394–400. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Sweeney DM, Manzi S, Janosky J, Selvaggi KJ, Ferri W, Medsger TA Jr and Ramsey-Goldman R: Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol. 22:1478–1482. 1995.PubMed/NCBI | |
|
Abu-Shakra M, Gladman DD and Urowitz MB: Malignancy in systemic lupus erythematosus. Arthritis Rheum. 39:1050–1054. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Mellemkler L, Andersen V, Linet MS, Gridley G, Hoover R and Olsen JH: Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 40:761–768. 1997.PubMed/NCBI View Article : Google Scholar | |
|
King JK and Costenbader KH: Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumato. 26:1491–1494. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Cush JJ: Rheumatoid arthritis: Early diagnosis and treatment. Med Clin North Am. 105:355–365. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R and Fraumeni JF Jr: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 85:307–311. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Isomäki HA, Hakulinen T and Joutsenlahti U: Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis. 31:691–696. 1978.PubMed/NCBI View Article : Google Scholar | |
|
Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H and Olsen JH: Rheumatoid arthritis and cancer. Eur J Cancer. 32A:1753–1757. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Kauppi M, Pukkala E and Isomäki H: Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control. 8:201–204. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Prior P: Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med. 78:15–21. 1985.PubMed/NCBI View Article : Google Scholar | |
|
Hakulinen T, Isomaki H and Knekt P: Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med. 78:29–32. 1985.PubMed/NCBI View Article : Google Scholar | |
|
Silman AJ, Petrie J, Hazleman B and Evans SJ: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis. 47:988–992. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N and Sibilia J: Investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France. Blood. 99:3909–3915. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Kinlen LJ: Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 78:44–49. 1985.PubMed/NCBI View Article : Google Scholar | |
|
Thorne I and Sutcliffe N: Sjögren's syndrome. Br J Hosp Med (Lond). 78:438–442. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, et al: 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 69:35–45. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sebastian A, Szachowicz A and Wiland P: Classification criteria for secondary Sjögren's syndrome. Current state of knowledge. Reumatologia. 57:277–280. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL and Chused TM: Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 89:888–892. 1978.PubMed/NCBI View Article : Google Scholar | |
|
Váróczy L, Páyer E, Kádár Z, Gergely L, Miltényi Z, Magyari F, Szodoray P and Illés A: Malignant lymphomas and autoimmunity-a single center experience from Hungary. Clin Rheumatol. 31:219–224. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zintzaras E, Voulgarelis M and Moutsopoulos H: The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med. 165:2337–2344. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Pertovaara M, Pukkala E, Laippala P, Miettinen A and Pasternack A: A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: Clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 60:467–472. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Bernatsky S, Ramsey-Goldman R and Clarke A: Malignancy and autoimmunity. Curr Opin Rheumatol. 18:129–134. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Shaffer AL, Rosenwald A and Staudt LM: Lymphoid malignancies: The dark side of B-cell differentiation. Nat Rev Immunol. 2:920–932. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Ekström K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A and Askling J: Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 48:963–970. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Grulich AE, Vajdic CM and Cozen W: Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 16:405–408. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Peng Z, Liang X, Lin X, Lin W, Lin Z and Wei S: Exploration of the molecular mechanisms, shared gene signatures, and MicroRNAs between systemic lupus erythematosus and diffuse large B cell lymphoma by bioinformatics analysis. Lupus. 31:1317–1327. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Yu L, Zhang X, Shang J and Duan X: Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma. Front Immunol. 13(1036239)2022.PubMed/NCBI View Article : Google Scholar | |
|
Mackay LR and Rose NR: Autoimmunity and lymphoma: Tribulations of B cells. Nature Immunol. 2:793–795. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M and Isaacson PG: Regression of primary lowgrade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 324:575–577. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Mariette X: Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: Chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis. 60:1007–1010. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Smedby KE, Baecklund E and Askling J: Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 15:2069–2077. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 423:356–361. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Bernatsky S, Clarke A and Ramsey-Goldman R: Malignancy and systemic lupuserythematosus. Curr Rheumatol Rep. 4:351–358. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Yamamoto K: Pathogenesis of Sjogren's syndrome. Autoimmun Rev. 2:13–18. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Baecklund E, Askling J, Rosenquist R, Ekbom A and Klareskog L: Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol. 16:254–261. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Lenz G and Staudt LM: Aggressive lymphomas. N Engl J Med. 362:1417–1429. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Jones SA and Jenkins BJ: Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 18:773–789. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Qin B, Zhou Z, He J, Yan C and Ding S: IL-6 inhibits starvation-induced autophagy via the STAT3/Bcl-2 signaling pathway. Sci Rep. 5(15701)2015.PubMed/NCBI View Article : Google Scholar | |
|
Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, et al: Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 107:4101–4108. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Cortes J and Kurzrock R: Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma. 26:251–259. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Khatri VP and Caligiuri MA: A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother. 46:239–244. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Emilie D, Zou W, Fior R, Llorente L, Durandy A, Crevon MC, Maillot MC, Durand-Gasselin I, Raphael M, Peuchmaur M and Galamaud P: Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity. Methods. 11:133–142. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, et al: Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph consortium. Lancet Oncol. 7:27–38. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Szodoray P and Jonsson R: The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol. 62:421–428. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, et al: Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood. 104:2247–2253. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C and Klareskog L: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54:692–701. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Bachman TR, Sawitzke AD, Perkins SL, Ward JH and Cannon GW: Methotrexate-associated lymphoma in patients with rheumatoid arthritis: Report of two cases. Arthritis Rheum. 39:325–329. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Baltus JA, Boersma JW, Hartman AP and Vandenbroucke JP: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up. Ann Rheum Dis. 42:368–373. 1983.PubMed/NCBI View Article : Google Scholar | |
|
Symmons DP, Ahern M, Bacon PA, Hawkins CF, Amlot PL, Jones EL, Prior P and Scott DL: Lymphoproliferative malignancy in rheumatoid arthritis: A study of 20 cases. Ann Rheum Dis. 43:132–135. 1984.PubMed/NCBI View Article : Google Scholar | |
|
Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, et al: Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph consortium. Blood. 111:4029–4038. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived O, Petri MA, et al: Lymphoma risk in systemic lupus: Effects of disease activity versus treatment. Ann Rheum Dis. 73:138–142. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wolfe F and Michaud K: Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50:1740–1751. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Leombruno JP, Einarson TR and Keystone EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 68:1136–1145. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, et al: Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 64:1414–1420. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Wolfe F and Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56:1433–1439. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, Maloisel F, Clauvel JP, Brouet JC and Mariette X: Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 90:766–775. 1997.PubMed/NCBI | |
|
Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon PA, Traverse-Glehen A, Thieblemont C, Baseggio L, Michallet AS, Coiffier B and Salles G: Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 24:5234–5241. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, et al: Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 101:2489–2495. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Smedby KE, Askling J, Mariette X and Baecklund E: Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med. 264:514–527. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF and Melnick A: A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 113:3397–3405. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, et al: PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 370:1008–1018. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Nogai H, Dörken B and Lenz G: Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 29:1803–1811. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Hiddemann W: Non-Hodgkin's lymphomas-current status of therapy and future perspectives. Eur J Cancer. 31A:2141–2145. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Nowakowski GS and Czuczman MS: ABC, GCB, and double-hit diffuse large B-cell lymphoma: Does subtype make a difference in therapy selection? Am Soc Clin Oncol Educ Book. 35:e449–e457. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 23:5027–5033. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 104:3064–3071. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 105:1417–1423. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346:235–242. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM, Blum KA, Shustov AR, Advani RH, Lih J, et al: The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, phase 2 study. Blood. 120(686)2012. | |
|
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115:2578–2585. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Valla K, Flowers CR and Koff JL: Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs. 27:513–522. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Aw A and Brown JR: Current status of Bruton's tyrosine kinase inhibitor development and use in B-cell malignancies. Drugs Aging. 34:509–527. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, et al: Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 28:4740–4746. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM and Ruggero D: Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci USA. 110:11988–11993. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Smolewski P and Rydygier D: Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies. Expert Opin Pharmacother. 21:1915–1926. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Kang MH and Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 19:202–208. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Vandenberg CJ and Cory S: ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 121:2285–2288. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lin VS, Xu ZF, Huang DCS and Thijssen R: BH3 mimetics for the treatment of B-cell malignancies-insights and lessons from the clinic. Cancers (Basel). 12(3353)2020.PubMed/NCBI View Article : Google Scholar | |
|
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, et al: Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 35:826–833. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Klanova M and Klener P: BCL-2 proteins in pathogenesis and therapy of B-cell non-Hodgkin lymphomas. Cancers (Basel). 12(938)2020.PubMed/NCBI View Article : Google Scholar | |
|
Nademanee A: Transplantation for non-Hodgkin lymphoma. Expert Rev Hematol. 2:425–442. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Bhatt VR and Vose JM: Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. Hematol Oncol Clin North Am. 28:1073–1095. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Turunen A, Valtola J, Partanen A, Ropponen A, Kuittinen O, Kuitunen H, Vasala K, Ågren L, Penttilä K, Keskinen L, et al: Autograft cellular composition and outcome in NHL patients: Results of the prospective multicenter GOA study. Leuk Lymphoma. 61:2082–2092. 2020.PubMed/NCBI View Article : Google Scholar |
